Skip to main content
. Author manuscript; available in PMC: 2019 Jan 17.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2014 Jun 28;41(10):1879–1888. doi: 10.1007/s00259-014-2791-x

Fig. 3.

Fig. 3

[18F]Fluciclatide PET/CT images of a right kidney tumor (arrows) in patient 10. Axial (a), sagittal (b) and coronal (c) images show abnormally increased uptake of [18F]fluciclatide within the tumor (SUV80% max 8.9). A renal tumor with a chromophobe component was confirmed by pathology